+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Doxorubicin Market Research Report by Application (Bone sarcoma, Breast cancer, and Endometrial cancer), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5336666
  • Report
  • July 2021
  • Region: Global
  • 189 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Doxorubicin Market will Grow to USD 3,257.68 Million by 2026, at a CAGR of 10.62%

FEATURED COMPANIES

  • Accord Healthcare
  • Cadila Pharmaceuticals
  • Getwell Oncology Pvt Ltd
  • Johnson & Johnson
  • Meiji Holdings Co., Ltd.
  • Pfizer, Inc.
The Global Doxorubicin Market size was estimated at USD 1,777.09 Million in 2020 and expected to reach USD 1,959.95 Million in 2021, at a Compound Annual Growth Rate (CAGR) 10.62% to reach USD 3,257.68 Million by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Doxorubicin to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Application, the Doxorubicin Market was examined across Bone sarcoma, Breast cancer, Endometrial cancer, Gastric cancer, Kaposi Sarcoma, Kidney cancer, Leukemia, Liver cancer, Multiple myeloma, and Ovarian cancer.
  • Based on Geography, the Doxorubicin Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Doxorubicin Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Doxorubicin Market, including Accord Healthcare, Allergan, Inc., Cadila Pharmaceuticals, Changzhou Kinyond Pharmaceutical Co., Ltd, Cipla, Inc., Dr. Reddy’s Laboratories Ltd., Getwell Oncology Pvt Ltd, Glenmark Pharmaceuticals Ltd., Janssen Products, LP, Johnson & Johnson, LGM Pharma, Manus Aktteva Biopharma LLP, Meiji Holdings Co., Ltd., Merrimack Pharmaceuticals, Inc., Novartis AG, Pfizer, Inc., SRS pharmaceuticals Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals, Thymoorgan Pharmazie GmbH, and TTY Biopharma.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Doxorubicin Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Doxorubicin Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Doxorubicin Market?
4. What is the competitive strategic window for opportunities in the Global Doxorubicin Market?
5. What are the technology trends and regulatory frameworks in the Global Doxorubicin Market?
6. What is the market share of the leading vendors in the Global Doxorubicin Market?
7. What modes and strategic moves are considered suitable for entering the Global Doxorubicin Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Accord Healthcare
  • Cadila Pharmaceuticals
  • Getwell Oncology Pvt Ltd
  • Johnson & Johnson
  • Meiji Holdings Co., Ltd.
  • Pfizer, Inc.
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Application Outlook
3.4. Geography Outlook
3.5. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing government support in technological advancement in clinical oncology
5.1.1.2. Growing cancer incidence rate
5.1.1.3. Increasing use in treating AIDS-related breast malignancy, Kaposi Sarcoma, multiple myeloma, and acute meroblastic leukemia
5.1.2. Restraints
5.1.2.1. Side effects of the drug and life-threatening conditions such as heart failure during or after therapy
5.1.3. Opportunities
5.1.3.1. Rising burden of cancer in Asian economies
5.1.3.2. Growing effort towards increasing awareness and drug availability
5.1.4. Challenges
5.1.4.1. Supply-demand gap in some areas of world
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Doxorubicin Market, by Application
6.1. Introduction
6.2. Bone sarcoma
6.3. Breast cancer
6.4. Endometrial cancer
6.5. Gastric cancer
6.6. Kaposi Sarcoma
6.7. Kidney cancer
6.8. Leukemia
6.9. Liver cancer
6.10. Multiple myeloma
6.11. Ovarian cancer

7. Americas Doxorubicin Market
7.1. Introduction
7.2. Argentina
7.3. Brazil
7.4. Canada
7.5. Mexico
7.6. United States

8. Asia-Pacific Doxorubicin Market
8.1. Introduction
8.2. Australia
8.3. China
8.4. India
8.5. Indonesia
8.6. Japan
8.7. Malaysia
8.8. Philippines
8.9. Singapore
8.10. South Korea
8.11. Thailand

9. Europe, Middle East & Africa Doxorubicin Market
9.1. Introduction
9.2. France
9.3. Germany
9.4. Italy
9.5. Netherlands
9.6. Qatar
9.7. Russia
9.8. Saudi Arabia
9.9. South Africa
9.10. Spain
9.11. United Arab Emirates
9.12. United Kingdom

10. Competitive Landscape
10.1. FPNV Positioning Matrix
10.1.1. Quadrants
10.1.2. Business Strategy
10.1.3. Product Satisfaction
10.2. Market Ranking Analysis
10.3. Market Share Analysis, By Key Player
10.4. Competitive Scenario
10.4.1. Merger & Acquisition
10.4.2. Agreement, Collaboration, & Partnership
10.4.3. New Product Launch & Enhancement
10.4.4. Investment & Funding
10.4.5. Award, Recognition, & Expansion

11. Company Usability Profiles
11.1. Accord Healthcare
11.2. Allergan, Inc.
11.3. Cadila Pharmaceuticals
11.4. Changzhou Kinyond Pharmaceutical Co., Ltd
11.5. Cipla, Inc.
11.6. Dr. Reddy’s Laboratories Ltd.
11.7. Getwell Oncology Pvt Ltd
11.8. Glenmark Pharmaceuticals Ltd.
11.9. Janssen Products, LP
11.10. Johnson & Johnson
11.11. LGM Pharma
11.12. Manus Aktteva Biopharma LLP
11.13. Meiji Holdings Co., Ltd.
11.14. Merrimack Pharmaceuticals, Inc.
11.15. Novartis AG
11.16. Pfizer, Inc.
11.17. SRS pharmaceuticals Pvt. Ltd.
11.18. Sun Pharmaceutical Industries Ltd.
11.19. Teva Pharmaceuticals
11.20. Thymoorgan Pharmazie GmbH
11.21. TTY Biopharma

12. Appendix
12.1. Discussion Guide
12.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL DOXORUBICIN MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION , 2020 (USD MILLION)
FIGURE 3. GLOBAL DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 4. GLOBAL DOXORUBICIN MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 5. GLOBAL DOXORUBICIN MARKET: MARKET DYNAMICS
FIGURE 6. GLOBAL DOXORUBICIN MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 7. GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION , 2020 VS 2026 (%)
FIGURE 8. GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION , 2020 VS 2026 (USD MILLION)
FIGURE 9. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION , 2026
FIGURE 10. GLOBAL DOXORUBICIN MARKET SIZE, BY BONE SARCOMA, 2018-2026 (USD MILLION)
FIGURE 11. GLOBAL DOXORUBICIN MARKET SIZE, BY BONE SARCOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 12. GLOBAL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, 2018-2026 (USD MILLION)
FIGURE 13. GLOBAL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 14. GLOBAL DOXORUBICIN MARKET SIZE, BY ENDOMETRIAL CANCER, 2018-2026 (USD MILLION)
FIGURE 15. GLOBAL DOXORUBICIN MARKET SIZE, BY ENDOMETRIAL CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 16. GLOBAL DOXORUBICIN MARKET SIZE, BY GASTRIC CANCER, 2018-2026 (USD MILLION)
FIGURE 17. GLOBAL DOXORUBICIN MARKET SIZE, BY GASTRIC CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 18. GLOBAL DOXORUBICIN MARKET SIZE, BY KAPOSI SARCOMA, 2018-2026 (USD MILLION)
FIGURE 19. GLOBAL DOXORUBICIN MARKET SIZE, BY KAPOSI SARCOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 20. GLOBAL DOXORUBICIN MARKET SIZE, BY KIDNEY CANCER, 2018-2026 (USD MILLION)
FIGURE 21. GLOBAL DOXORUBICIN MARKET SIZE, BY KIDNEY CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 22. GLOBAL DOXORUBICIN MARKET SIZE, BY LEUKEMIA, 2018-2026 (USD MILLION)
FIGURE 23. GLOBAL DOXORUBICIN MARKET SIZE, BY LEUKEMIA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 24. GLOBAL DOXORUBICIN MARKET SIZE, BY LIVER CANCER, 2018-2026 (USD MILLION)
FIGURE 25. GLOBAL DOXORUBICIN MARKET SIZE, BY LIVER CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 26. GLOBAL DOXORUBICIN MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2026 (USD MILLION)
FIGURE 27. GLOBAL DOXORUBICIN MARKET SIZE, BY MULTIPLE MYELOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 28. GLOBAL DOXORUBICIN MARKET SIZE, BY OVARIAN CANCER, 2018-2026 (USD MILLION)
FIGURE 29. GLOBAL DOXORUBICIN MARKET SIZE, BY OVARIAN CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 30. AMERICAS DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 31. AMERICAS DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 33. ARGENTINA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 34. BRAZIL DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 35. CANADA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 36. MEXICO DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 37. UNITED STATES DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 38. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 39. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 40. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 41. AUSTRALIA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 42. CHINA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 43. INDIA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 44. INDONESIA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 45. JAPAN DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 46. MALAYSIA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 47. PHILIPPINES DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 48. SINGAPORE DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 49. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 50. THAILAND DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 51. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 52. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 53. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 54. FRANCE DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 55. GERMANY DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 56. ITALY DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 57. NETHERLANDS DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 58. QATAR DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 59. RUSSIA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 60. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 61. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 62. SPAIN DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 63. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 64. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 65. GLOBAL DOXORUBICIN MARKET: FPNV POSITIONING MATRIX
FIGURE 66. GLOBAL DOXORUBICIN MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 67. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL DOXORUBICIN MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL DOXORUBICIN MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL DOXORUBICIN MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 5. GLOBAL DOXORUBICIN MARKET SIZE, BY BONE SARCOMA, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL DOXORUBICIN MARKET SIZE, BY ENDOMETRIAL CANCER, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL DOXORUBICIN MARKET SIZE, BY GASTRIC CANCER, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL DOXORUBICIN MARKET SIZE, BY KAPOSI SARCOMA, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL DOXORUBICIN MARKET SIZE, BY KIDNEY CANCER, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL DOXORUBICIN MARKET SIZE, BY LEUKEMIA, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL DOXORUBICIN MARKET SIZE, BY LIVER CANCER, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL DOXORUBICIN MARKET SIZE, BY MULTIPLE MYELOMA, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL DOXORUBICIN MARKET SIZE, BY OVARIAN CANCER, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 15. AMERICAS DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 16. AMERICAS DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 17. ARGENTINA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 18. BRAZIL DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 19. CANADA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 20. MEXICO DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 21. UNITED STATES DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 22. UNITED STATES DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 23. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 24. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 25. AUSTRALIA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 26. CHINA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 27. INDIA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 28. INDONESIA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 29. JAPAN DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 30. MALAYSIA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 31. PHILIPPINES DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 32. SINGAPORE DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 33. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 34. THAILAND DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 36. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 37. FRANCE DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 38. GERMANY DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 39. ITALY DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 40. NETHERLANDS DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 41. QATAR DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 42. RUSSIA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 43. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 44. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 45. SPAIN DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 46. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 47. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY APPLICATION , 2018-2026 (USD MILLION)
TABLE 48. GLOBAL DOXORUBICIN MARKET: SCORES
TABLE 49. GLOBAL DOXORUBICIN MARKET: BUSINESS STRATEGY
TABLE 50. GLOBAL DOXORUBICIN MARKET: PRODUCT SATISFACTION
TABLE 51. GLOBAL DOXORUBICIN MARKET: RANKING
TABLE 52. GLOBAL DOXORUBICIN MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 53. GLOBAL DOXORUBICIN MARKET: MERGER & ACQUISITION
TABLE 54. GLOBAL DOXORUBICIN MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 55. GLOBAL DOXORUBICIN MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 56. GLOBAL DOXORUBICIN MARKET: INVESTMENT & FUNDING
TABLE 57. GLOBAL DOXORUBICIN MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 58. GLOBAL DOXORUBICIN MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Accord Healthcare
  • Allergan, Inc.
  • Cadila Pharmaceuticals
  • Changzhou Kinyond Pharmaceutical Co., Ltd
  • Cipla, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Getwell Oncology Pvt Ltd
  • Glenmark Pharmaceuticals Ltd.
  • Janssen Products, LP
  • Johnson & Johnson
  • LGM Pharma
  • Manus Aktteva Biopharma LLP
  • Meiji Holdings Co., Ltd.
  • Merrimack Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • SRS pharmaceuticals Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals
  • Thymoorgan Pharmazie GmbH
  • TTY Biopharma
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll